

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Source Precision Medicine, Inc. d/b/a Source MDx	05/05/2011

RECEIVING PARTY DATA

Name:	Life Technologies Corporation
Street Address:	5791 Van Allen Way
City:	Carlsbad
State/Country:	CALIFORNIA
Postal Code:	92008

PROPERTY NUMBERS Total: 11

Property Type	Number
Patent Number:	6692916
Patent Number:	6960439
Patent Number:	6964850
Application Number:	10703143
Application Number:	10701391
Application Number:	10742458
Application Number:	11159376
Application Number:	11454553
Application Number:	11827892
Application Number:	12609578
Application Number:	95001032

CORRESPONDENCE DATA

Fax Number: (512)721-3838
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
 Phone: 512-721-3742

CH \$440.00 6692916

501523444

**PATENT
 REEL: 026238 FRAME: 0857**

Email: tracy.sauers@lifetech.com
Correspondent Name: Tracy Sauers
Address Line 1: Life Technologies Corporation
Address Line 2: 2130 Woodward St., Mail Stop 650
Address Line 4: Austin, TEXAS 78744

ATTORNEY DOCKET NUMBER:

SOURCE MDX

NAME OF SUBMITTER:

Tracy Sauers

Total Attachments: 21

source=Source Life Tech Patent Assignment#page1.tif
source=Source Life Tech Patent Assignment#page2.tif
source=Source Life Tech Patent Assignment#page3.tif
source=Source Life Tech Patent Assignment#page4.tif
source=Source Life Tech Patent Assignment#page5.tif
source=Source Life Tech Patent Assignment#page6.tif
source=Source Life Tech Patent Assignment#page7.tif
source=Source Life Tech Patent Assignment#page8.tif
source=Source Life Tech Patent Assignment#page9.tif
source=Source Life Tech Patent Assignment#page10.tif
source=Source Life Tech Patent Assignment#page11.tif
source=Source Life Tech Patent Assignment#page12.tif
source=Source Life Tech Patent Assignment#page13.tif
source=Source Life Tech Patent Assignment#page14.tif
source=Source Life Tech Patent Assignment#page15.tif
source=Source Life Tech Patent Assignment#page16.tif
source=Source Life Tech Patent Assignment#page17.tif
source=Source Life Tech Patent Assignment#page18.tif
source=Source Life Tech Patent Assignment#page19.tif
source=Source Life Tech Patent Assignment#page20.tif
source=Source Life Tech Patent Assignment#page21.tif

ASSIGNMENT OF PATENTS AND PATENT APPLICATIONS

This Assignment of Patents and Patent Applications ("Patent Assignment"), effective as of May 4, 2011 (the "Effective Date"), is by and between Joseph F. Finn, Jr., as assignee for the benefit of creditors (the "Seller.") of Source Precision Medicine, Inc. (d/b/a "Source MDx") a Delaware corporation (the "Company"), and Life Technologies Corporation, a Delaware corporation (the "Buyer").

WHEREAS, the Buyer and the Seller are parties to that certain Bill of Sale and Sale Agreement, dated as of the date hereof (the "Sale Agreement");

WHEREAS, pursuant to the Sale Agreement, the Seller has agreed to execute and deliver this Patent Assignment;

WHEREAS, the Seller is the owner of the right, title and interest in and to certain patents (the "Patents") and certain patent applications (the "Patent Applications"), each as specified in Schedule 1 attached hereto, subject to any and all liens and encumbrances relating to such Patents and Patent Applications previously granted by the Company;

WHEREAS, the Seller is willing to assign to the Buyer its respective rights in such Patents and Patent Applications;

WHEREAS, the Buyer desires to obtain ownership of the Patents and Patent Applications in accordance with the terms and conditions set forth in this Patent Assignment and the Sale Agreement.

NOW, THEREFORE, in consideration of the premises and mutual covenants and agreements hereinafter set forth, the sufficiency of which is acknowledged, the Buyer and the Seller, intending to be legally bound, hereby agree as follows:

1. Assignment. The Seller does hereby irrevocably grant, sell, convey, transfer, assign, deliver and relinquish exclusively to the Buyer, in perpetuity, all of its respective worldwide right, title, and interest in and to all of the Patents and Patent Applications, together with (i) the right to sue for and obtain remedies against past infringement and rights of priority and protection of interest in such Patents and Patent Applications and (ii) the right to file and obtain any continuations, continuations-in-part, reissues, patent term extensions, divisionals and reexamination of the Patents and Patent Applications, as applicable.

2. Recordation. In order to record this Patent Assignment with the United States Patent and Trademark Office (the "PTO"), the parties hereto shall execute this Patent Assignment and the Buyer shall execute the Recordation Cover Sheet required by the PTO in order to record the assignment effected hereby. Thereafter, the Buyer shall record the executed Recordation Form Cover Sheet with the PTO, together with any schedules and exhibits thereto, including, but not limited to, this Patent Assignment and Schedule 1 hereto.

3. Power of Attorney. The Seller does hereby make, constitute and appoint the Buyer (and any officer or agent of the Buyer as the Buyer may select in its exclusive discretion) as the Seller's true and lawful attorney-in-fact, with the power to endorse the Seller's name on all

applications, documents, papers and instruments necessary to implement and effect fully the intentions, purposes and provisions of this Patent Assignment, including, but not limited to, the filing of any instrument of assignment and documents related thereto to effect such assignment in the PTO; provided, that the Buyer shall only be entitled to exercise its rights under this power of attorney with respect to any of the foregoing actions to the extent that the Seller has failed to take such action at the request of the Buyer and following ten (10) days prior written notice to the Seller of the exercise of such rights. This power of attorney shall be irrevocable.

4. “AS IS” AND “WHERE IS”. EXCEPT AS SET FORTH IN THE SALE AGREEMENT, THE PATENT AND PATENT APPLICATIONS ARE ASSIGNED WITHOUT ANY REPRESENTATIONS OR WARRANTIES OR GUARANTY OF ANY KIND WHATSOEVER, INCLUDING BUT NOT LIMITED TO ANY EXPRESS OR IMPLIED REPRESENTATIONS OR WARRANTIES CONCERNING TITLE, QUALITY, QUANTITY, DURABILITY, CONDITION, MERCHANTABILITY, FITNESS FOR ANY PURPOSE, FREEDOM TO OPERATE, DEPENDENT TECHNOLOGY, NON-INFRINGEMENT, VALIDITY OR ANY OTHER ASPECT OF THE SAME. FURTHER, THE PATENT AND PATENT APPLICATIONS ARE ASSIGNED "AS IS" AND "WHERE IS" WITHOUT REPRESENTATION OR WARRANTY AND ALL WARRANTIES EXPRESS, IMPLIED OR ARISING BY OPERATION OF LAW, ARE HEREBY EXPRESSLY DISCLAIMED, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. THE ASSIGNEE ASSUMES NO RESPONSIBILITY FOR THE CONDITION OR POTENTIAL (OR LACK THEREOF) OF THE PATENT AND PATENT APPLICATIONS. THE PATENT AND PATENT APPLICATIONS MAY BE SUBJECT TO CERTAIN PRE-EXISTING LIENS AND ENCUMBRANCES. SELLER SHALL HAVE NO LIABILITY WHATSOEVER CONCERNING THE PATENT AND PATENT APPLICATIONS, INCLUDING LIABILITY FOR NEGLIGENCE OR ANY OTHER THEORY OF LIABILITY OR CAUSE OF ACTION. IN NO EVENT SHALL SELLER BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY, OR SPECIAL DAMAGES ARISING IN ANY WAY WITH RESPECT TO THE PATENT AND PATENT APPLICATIONS, EVEN IF SELLER HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

5. Governing Law. This Patent Assignment shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts and any suit or action hereunder, except as otherwise set forth herein, shall be brought in said jurisdiction.


6. Successors and Assigns. This Patent Assignment shall bind the Seller and its successors and assigns and inure to the benefit of Buyer and its successors and assigns.

7. Counterparts; Execution. This Patent Assignment may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. Facsimile and electronic (i.e., .pdf format) signatures shall be as effective as original signatures.

[Signature page to follow]

This Assignment of Patents and Patent Applications is executed and delivered effective as of the date first set forth above.

**SELLER AS ASSIGNEE FOR THE
BENEFIT OF CREDITORS OF SOURCE
PRECISION MEDICINE, INC., D/B/A
SOURCE MDX**

By: 
Joseph F. Finn, Jr., as and only as assignee
for the benefit of creditors of Source
Precision Medicine, Inc., d/b/a "Source
MDx", and not individually.

LIFE TECHNOLOGIES CORPORATION

By: _____
Name: Kimberlee Caple
Title: Head of Medical Marketing

5791 Van Allen Way
Carlsbad, CA 92008

Telephone: (760) 603-7200
Fax: (760) 602-6500

This Assignment of Patents and Patent Applications is executed and delivered effective as of the date first set forth above.

**SELLER AS ASSIGNEE FOR THE
BENEFIT OF CREDITORS OF SOURCE
PRECISION MEDICINE, INC., D/B/A
SOURCE MDX**

By: _____
Joseph F. Finn, Jr., as and only as assignee
for the benefit of creditors of Source
Precision Medicine, Inc., d/b/a "Source
MDx", and not individually.

LIFE TECHNOLOGIES CORPORATION

By: Kimberlee Caple
Name: Kimberlee Caple
Title: Head of Medical Marketing

5791 Van Allen Way
Carlsbad, CA 92008


Telephone: (760) 603-7200
Fax: (760) 602-6500

[SIGNATURE PAGE - ASSIGNMENT OF PATENTS AND PATENT APPLICATIONS]

COUNTY OF [Suffolk] :

STATE OF [MASSACHUSETTS] : ss.:

BE IT REMEMBERED, that on this 5th day of MAY, ²⁰¹¹~~200~~, before me, the subscriber, a notary public of the Commonwealth of Massachusetts, personally appeared JOSEPH F. FINN, JR. [and _____], who, I am satisfied, is[/are] the person[s] who signed the foregoing Bill of Sale and Sale Agreement as the assignee for the benefit of creditors of Source Precision Medicine, Inc., d/b/a Source MDx, the Seller named therein, and he thereupon acknowledged that the said instrument made by the Seller was signed, sealed with the corporate seal and delivered by him as such officer and is the voluntary act and deed of the Seller.

 _____ Notary
Public

ROGER J. DEVEAU

MY COMMISSION EXPIRES : 10/05/2012

Schedule 1

Patents and Patent Applications

- A. US Patent 6,692,916
- B. US Patent 6,960,439
- C. US Patent 6,964,850
- D. Foundational patents include (i) any worldwide counterparts of US Patent 6,692,916, US Patent 6,960,439 and US Patent 6,964,850, (ii) any substitutions, continuations, continuations-in-part, or divisional of the foregoing, (iii) any patents, worldwide, issuing on any of the foregoing, (iv) any reissues, re-examinations and extensions thereof, (v) all priority applications of the foregoing and any patent applications or patents seeking priority to those priority applications, and (vi) any patents or patent applications with substantially similar disclosure of the foregoing; in each case, including, without limitation, those items included on Annex I attached to this Schedule 1.

For the avoidance of doubt, the Patent and Patent Applications also include any patent applications related to any of the foregoing (including, without limitation, any such related patent applications disclosed in the Bidder's Package).

Foundational patents are supplemented with Source MDx general laboratory process documents, including:

- a. *Process Flow Diagrams*
 - Clinical sample receipt
 - Sample processing
 - Plate manufacturing and quality control
 - Replicate data filtering
 - Process overview white paper
- b. *Standard Operating Procedures (levels 1-3)*
 - General & Administrative - 8 SOPs
 - Laboratory – 44 SOPs
 - Clinical – 8 SOPs
 - Information Technology – 27 SOPs

Patent List

Docket Number/Subcase
Country Name

Case
Type

Serial Number
Filing Date

Publication
Number/Date

Patent
Number/Date

Status
Expiration Date

33743-501/D01
India

DIV 3792/CHENP/2008
19-Dec-2003

Owner Name: Source Precision Medicine, Inc.
Client Name: Source MDX

Agent Name: DePenning & DePenning/Chennai

Title: Systems And Methods For Characterizing A Biological
Condition Or Agent Using Precision Gene Expression
Profiles

Client Ref: 4059-2008/LP/ac
Agent Ref:

Attorney(s): IRE CAK LLM
JRC IF KAH

Pending

33743-501/D01
Japan

DIV 2010-111560 2010-227111
19-Dec-2003 14-Oct-2010

Owner Name: Source Precision Medicine, Inc.
Client Name: Source MDX

Agent Name: Shusaku Yamamoto/Osaka

Title: Systems And Methods For Characterizing A Biological
Condition Or Agent Using Precision Gene Expression
Profiles

Client Ref: F1-10A46AZY
Agent Ref:

Attorney(s): IRE CAK LLM
JRC IF KAH

Published

33743-501/
United States of America

CIP 10/742458 2005-0060101
19-Dec-2003 17-Mar-2005

Owner Name: Source Precision Medicine, Inc.
Client Name: Source MDX

Agent Name:

Title: Systems And Methods For Characterizing A Biological
Condition Or Agent Using Precision Gene Expression
Profiles

Client Ref: 2331/126
Agent Ref:

Attorney(s): IRE CAK LLM
JRC IF KAH

Published

Patent List

Docket Number/Subcase Country Name	Case Type	Serial Number Filing Date	Publication Number/Date	Patent Number/Date	Status Expiration Date
33743-501 PRO/004 Australia	PCT	2003303238 19-Dec-2003	22-Jul-2010	2003303238 04-Nov-2010	Granted 19-Dec-2023
<i>Owner Name:</i> Source Precision Medicine, Inc.					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i> Griffith Hack/Melbourne					
<i>Title:</i> Identification, Monitoring and Treatment of Infectious Disease and Characterization of Inflammatory Conditions Related to Infectious Disease Using Gene Expression Profiles					
33743-501 PRO/007 Brazil	PCT	P10317612-6 19-Dec-2003	06-Dec-2005		Published
<i>Owner Name:</i> Source Precision Medicine, Inc.					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i> Dannemann Siemsen/Rio					
<i>Title:</i> Identification, Monitoring And Treatment Of Disease And Characterization Of Biological Condition Using Gene Expression Profiles					
33743-501 PRO/008 Canada	PCT	2511237 19-Dec-2003			Pending 19-Dec-2023
<i>Owner Name:</i> Source Precision Medicine, Inc.					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i> Gowling Lafleur/Ottawa					
<i>Title:</i> Identification, Monitoring And Treatment Of Disease And Characterization Of Biological Condition Using Gene Expression Profiles					
<i>Client Ref:</i> 2331/126CA					
<i>Agent Ref:</i> L80002609CA					

Patent List

Docket Number/Subcase Country Name	Case Type	Serial Number Filing Date	Publication Number/Date	Patent Number/Date	Status Expiration Date
33743-501 PRO/010 China (People's Republic)	PCT	200380109850.5 19-Dec-2003	CN1751129A 22-Mar-2006		Published 19-Dec-2023
<i>Owner Name:</i> Source Precision Medicine, Inc.					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i> China Science Patent & Trademark Agent Ltd.					
<i>Title:</i> Identification, Monitoring And Treatment Of Disease And Characterization Of Biological Condition Using Gene Expression Profiles					
33743-501 PRO/019 European Patent Convention	PCT	03808491.9 19-Dec-2003	1579008 28-Sep-2005		Published 19-Dec-2023
<i>Owner Name:</i> Source Precision Medicine, Inc.					
<i>Client Name:</i> Source MDX					
<i>Agent Ref:</i> 2331/126EP					
<i>Title:</i> Identification, Monitoring And Treatment Of Disease And Characterization Of Biological Condition Using Gene Expression Profiles					
33743-501 PRO/030 India	PCT	1619/CHENP/2005 19-Dec-2003	234094 05-May-2009		Granted 19-Dec-2023
<i>Owner Name:</i> Source Precision Medicine, Inc.					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i> DePenning & DePenning/Chennai					
<i>Title:</i> Identification, Monitoring And Treatment Of Disease And Characterization Of Biological Condition Using Gene Expression Profiles					
<i>Client Ref:</i> 2331/126IN					
<i>Agent Ref:</i> 1619P-05 DJS/md					

Patent List

Docket Number/Subcase Country Name	Case Type	Serial Number Filing Date	Publication Number/Date	Patent Number/Date	Status Expiration Date
33743-501 PRO/032 Japan	PCT	2004-562300 19-Dec-2003	06-510382 30-Mar-2006		Published 19-Dec-2023
<i>Owner Name:</i> Source Precision Medicine, Inc.					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i> Shusaku Yamamoto/Osaka					
<i>Title:</i> Identification, Monitoring And Treatment Of Disease And Characterization Of Biological Condition Using Gene Expression Profiles					
33743-501 PRO/042 Mexico	PCT	2005/006804 19-Dec-2003			Pending 19-Dec-2023
<i>Owner Name:</i> Source Precision Medicine, Inc.					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i> Becerril, Coca & Becerril, SC					
<i>Title:</i> Identification, Monitoring And Treatment Of Disease And Characterization Of Biological Condition Using Gene Expression Profiles					
33743-503/004 Australia	PCT	58985/00 28-Jun-2000	784233 23-Feb-2006	784233 22-Jun-2006	Granted 28-Jun-2020
<i>Owner Name:</i> Source Precision Medicine, Inc.					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i> Griffith Hack/Melbourne					
<i>Title:</i> System And Methods For Characterizing A Biological Condition Or Agent Using Calibrated Gene Expression Profiles					
<i>Client Ref:</i> 2331/109AU					
<i>Agent Ref:</i> AIS:JK:P44504					

Patent List

Docket Number/Subcase
Country Name

Case
Type

Serial Number
Filing Date

Publication
Number/Date

Patent
Number/Date

Status
Expiration Date

33743-503/008
Canada

PCT 2378008
28-Jun-2000

Owner Name: Source Precision Medicine, Inc.
Client Name: Source MDX

Agent Name: Gowling Lafleur/Ottawa

Title: System And Methods For Characterizing A Biological
Condition Or Agent Using Calibrated Gene Expression
Profiles

Client Ref: 2331/109CA
Agent Ref: 08893607CA

Pending
28-Jun-2020
Attorney(s): IRE CAK LLM
JRC IF KAH

33743-503/029
Israel

PCT 147349
28-Jun-2000

Owner Name: Source Precision Medicine, Inc.
Client Name: Source MDX

Agent Name: Dr. Shlomo Cohen & Co.

Title: System And Methods For Characterizing A Biological
Condition Or Agent Using Calibrated Gene Expression
Profiles

Client Ref: 2331/109IL
Agent Ref: 09710/0009,000

Pending
28-Jun-2020
Attorney(s): IRE CAK LLM
JRC IF KAH

33743-503/032
Japan

PCT 2001-528624
28-Jun-2000

Owner Name: Source Precision Medicine, Inc.
Client Name: Source MDX

Agent Name: Yamasaki Law & Patent Office

Title: System And Methods For Characterizing A Biological
Condition Or Agent Using Calibrated Gene Expression
Profiles

Client Ref: 2331/109JP
Agent Ref: P6722

Published
28-Jun-2020
Attorney(s): IRE CAK LLM
JRC IF KAH

Thursday, May 05, 2011

Patent List

Page: 6

Docket Number/Subcase
Country Name

Case
Type

Serial Number
Filing Date

Publication
Number/Date

Patent
Number/Date

Status
Expiration Date

33743-503/054
Singapore

PCT
200107981-3
28-Jun-2000

200107981-3
28-Jun-2000

85924
30-Jun-2006

Granted
28-Jun-2020

Owner Name: Source Precision Medicine, Inc.

Attorney(s): IRE CAK
JRC IF

LLM

Client Name: Source MDX

Client Ref: 2331/109SG

KAH

Agent Name: Henry Goh (S) Pte Ltd/Singapor

Title: System And Methods For Characterizing A Biological
Condition Or Agent Using Calibrated Gene Expression
Profiles

Agent Ref: SP-1289

System And Methods For Characterizing A Biological
Condition Or Agent Using Calibrated Gene Expression
Profiles

33743-503 CIP/
United States of America

CIP
09/821850
29-Mar-2001

09/821850
29-Mar-2001

2003-0229455
11-Dec-2003

6,692,916
17-Feb-2004

Granted

Owner Name: Source Precision Medicine, Inc.

Attorney(s): IRE CAK
JRC IF

LLM

Client Name: Source MDX

Agent Name:

Title: SYSTEM AND METHODS FOR CHARACTERIZING A
BIOLOGICAL CONDITION OR AGENT USING
PRECISION GENE EXPRESSION PROFILES

Client Ref: 2331/1112

KAH

33743-503 CIP 2/
United States of America

CIP
10/291225
08-Nov-2002

10/291225
08-Nov-2002

2004-0133352
08-Jul-2004

6,960,439
01-Nov-2005

Granted

Owner Name: Source Precision Medicine, Inc.

Attorney(s): IRE CAK
JRC IF

LLM

Agent Name:

Title: Identification, Monitoring And Treatment Of Disease
And Characterization Of Biological Condition Using Gene
Expression Profiles

Client Ref: 2331/1120

KAH

Identification, Monitoring And Treatment Of Disease
And Characterization Of Biological Condition Using Gene
Expression Profiles

Patent List

Docket Number/Subcase Country Name	Case Type	Serial Number Filing Date	Publication Number/Date	Patent Number/Date	Status Expiration Date
33743-503 CIP DIV/ United States of America	DIV	10/703143 03-Nov-2003	2004-0219568 04-Nov-2004		Published
<i>Owner Name:</i> Source Precision Medicine, Inc.					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i>					
<i>Title:</i> System And Methods For Characterizing A Biological Condition Or Agent Using Selected Gene Expression Profiles					
33743-503 CIP DIV 2/ United States of America	DIV	10/701391 03-Nov-2003	2004-0224322 11-Nov-2004		Published
<i>Owner Name:</i> Source Precision Medicine, Inc.					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i>					
<i>Title:</i> System And Methods For Characterizing A Biological Condition Or Agent Using Selected Gene Expression Profiles					
33743-504/D01 Japan	DIV	2010-254661 08-Nov-2002	2011-067214 07-Apr-2011		Published
<i>Owner Name:</i>					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i> Yamasaki Law & Patent Office					
<i>Title:</i> Identification, Monitoring And Treatment Of Disease And Characterization Of Biological Condition Using Gene Expression Profiles					
<i>Client Ref:</i> P8544					
<i>Agent Ref:</i> P8544					
<i>Attorney(s):</i> IRE CAK LLM JRC IF KAH					
<i>Client Ref:</i> 2331/122					
<i>Agent Ref:</i> 2331/123					
<i>Attorney(s):</i> IRE CAK LLM JRC IF KAH					

Patent List

Docket Number/Subcase Country Name	Case Type	Serial Number Filing Date	Publication Number/Date	Patent Number/Date	Status Expiration Date
33743-504/ United States of America	ORD	10/291856 08-Nov-2002	2003-0219771 27-Nov-2003	6,964,850 15-Nov-2005	Granted
<i>Owner Name:</i> Source MDX					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i>					
<i>Title:</i> Identification, Monitoring And Treatment Of Disease And Characterization Of Biological Condition Using Gene Expression Profiles					
<i>Client Ref:</i> 2331/1119					
<i>Agent Ref:</i>					
33743-504/C03 United States of America	CON	12/609578 30-Oct-2009	2010-0086935 08-Apr-2010		Published
<i>Owner Name:</i> Source MDX					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i>					
<i>Title:</i> Identification, Monitoring And Treatment Of Disease And Characterization Of Biological Condition Using Gene Expression Profiles					
<i>Client Ref:</i>					
<i>Agent Ref:</i>					
33743-504/RE1 United States of America	REX	95/001032 17-Mar-2008		6,964,850	Pending
<i>Owner Name:</i> Source MDX					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i>					
<i>Title:</i> Identification, Monitoring And Treatment Of Disease And Characterization Of Biological Condition Using Gene Expression Profiles					
<i>Client Ref:</i>					
<i>Agent Ref:</i>					

Patent List

Docket Number/Subcase Country Name	Case Type	Serial Number Filing Date	Publication Number/Date	Patent Number/Date	Status Expiration Date
33743-504 CON 2/ United States of America	CON	11/159376 22-Jun-2005	2005-0250148 10-Nov-2005		Allowed

Owner Name: Source MDX
Client Name: Source MDX
Attorney(s): IRE CAK LLM
 JRC IF

Agent Name: 2331/135
Client Ref: 2331/135

Title: Identification, Monitoring And Treatment Of Disease
 And Characterization Of Biological Condition Using Gene
 Expression Profiles

33743-504 PRO A/008
 Canada

PCT 2466502
 08-Nov-2002
Owner Name: Source MDX
Client Name: Source MDX
Attorney(s): IRE CAK LLM
 JRC IF

Agent Name: 2331/119CA
Client Ref: L80001926CA

Title: Identification, Monitoring And Treatment Of Disease
 And Characterization Of Biological Condition Using Gene
 Expression Profiles

33743-504 PRO A/010
 China (People's Republic)

PCT 02826908 X
 08-Nov-2002
Owner Name: Source MDX
Client Name: Source MDX
Attorney(s): IRE CAK LLM
 JRC IF

Agent Name: 2331/119CN
Client Ref: MA10-P04/1454

Title: Identification, Monitoring And Treatment Of Disease
 And Characterization Of Biological Condition Using Gene
 Expression Profiles

Pending
 08-Nov-2022

Published
 08-Nov-2022

Thursday, May 05, 2011

Patent List

Page: 10

Docket Number/Subcase Country Name	Case Type	Serial Number Filing Date	Publication Number/Date	Patent Number/Date	Status Expiration Date
33743-504 PRO A/019 European Patent Convention	PCT	02792239.2 08-Nov-2002	1451340 01-Sep-2004		Published 08-Nov-2022
<i>Owner Name:</i> Source MDX					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i>					
<i>Title:</i> Identification, Monitoring And Treatment Of Disease And Characterization Of Biological Condition Using Gene Expression Profiles					
<i>Client Ref:</i> 2331/119EP					
<i>Agent Ref:</i>					
33743-504 PRO A/030 India	PCT	984/CHENP/2004 08-Nov-2002		227975 27-Jan-2009	Granted 08-Nov-2022
<i>Owner Name:</i> Source MDX					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i> DePenning & DePenning/Chennai					
<i>Title:</i> Identification, Monitoring And Treatment Of Disease And Characterization Of Biological Condition Using Gene Expression Profiles					
<i>Client Ref:</i> 2331/119IN					
<i>Agent Ref:</i> 1266-2004					
33743-504 PRO A/032 Japan	PCT	2003-542649 08-Nov-2002	2005508505 31-Mar-2005		Published 08-Nov-2022
<i>Owner Name:</i> Source MDX					
<i>Client Name:</i> Source MDX					
<i>Agent Name:</i> Yamasaki Law & Patent Office					
<i>Title:</i> Identification, Monitoring And Treatment Of Disease And Characterization Of Biological Condition Using Gene Expression Profiles					
<i>Client Ref:</i> 2331/119JP					
<i>Agent Ref:</i> P7176					
<i>Attorney(s):</i> IRE CAK LLM					
<i>Attorney(s):</i> JRC IF KAH					

Docket Number/Subcase
Country Name

Case
Type

Serial Number
Filing Date

Publication
Number/Date

Patent
Number/Date

Status
Expiration Date

33743-507/001
Australia

PCT 2006259306
16-Jun-2006

Pending
16-Jun-2026

Owner Name: Source MDX
Client Name: Source MDX

Attorney(s): IRE CAK LLM
JRC IF KAH

Agent Name: Cullens/Brisbane

Title: Gene Expression Profiling For Identification And
Monitoring Of Multiple Sclerosis

Client Ref:
Agent Ref: 072256AU/KF

33743-507/002
Australia

PCT 2007272824
13-Jul-2007

Pending
13-Jul-2027

Owner Name: Source MDX
Client Name: Source MDX

Attorney(s): IRE CAK LLM
JRC IF KAH

Agent Name: Cullens/Brisbane

Title: Gene Expression Profiling For Identification, Monitoring
And Treatment Of Multiple Sclerosis

Client Ref:
Agent Ref: 090019AU/KF

33743-507/001
Canada

PCT 2612492
16-Jun-2006

Pending
16-Jun-2026

Owner Name: Source MDX
Client Name: Source MDX

Attorney(s): IRE CAK LLM
JRC IF KAH

Agent Name: Ridout & Maybee/Mississauga

Title: Gene Expression Profiling For Identification And
Monitoring Of Multiple Sclerosis

Client Ref:
Agent Ref: 33651-0184

Thursday, May 05, 2011

Patent List

Page: 12

Docket Number/Subcase
Country Name

Case
Type

Serial Number
Filing Date

Publication
Number/Date

Patent
Number/Date

Status
Expiration Date

33743-507/002
Canada

PCT
2658171
13-Jul-2007

2062981
27-May-2009

Pending
13-Jul-2027

IRE CAK LLM
JRC IF

Owner Name:
Client Name: Source MDX

Attorney(s): IRE CAK LLM
JRC IF

Agent Name: Ridout & Maybee/Otawa
Title: Gene Expression Profiling For Identification, Monitoring
And Treatment Of Multiple Sclerosis

Client Ref:
Agent Ref: 33651-0235

33743-507/002
European Patent Convention

PCT
07810433.8
13-Jul-2007

2069533
17-Jun-2009

Published
13-Jul-2027

IRE CAK LLM
JRC IF

Owner Name:
Client Name: Source MDX

Attorney(s): IRE CAK LLM
JRC IF

Agent Name: Mintz Levin London
Title: Gene Expression Profiling For Identification, Monitoring
And Treatment Of Multiple Sclerosis

Client Ref:
Agent Ref:

33743-507/D01
European Patent Convention

PCT
09154300.9
16-Jun-2006

2062981
27-May-2009

Published

IRE CAK LLM
JRC IF

Owner Name:
Client Name: Source MDX

Attorney(s): IRE CAK LLM
JRC IF

Agent Name:
Title: Gene Expression Profiling For Identification And
Monitoring Of Multiple Sclerosis

Client Ref:
Agent Ref:

Thursday, May 05, 2011

Patent List

Page: 13

Docket Number/Subcase
Country Name

Case
Type

Serial Number
Filing Date

Publication
Number/Date

Patent
Number/Date

Status
Expiration Date

33743-507/
United States of America

CON
11/454553
16-Jun-2006

2008-0070243
20-Mar-2008

Published

IRE CAK LLM
JRC IF

Owner Name:
Client Name: Source MDX

Attorney(s): IRE CAK LLM
JRC IF
KAH

Agent Name:

Title: Gene Expression Profiling For Identification, Monitoring
And Treatment Of Multiple Sclerosis

Client Ref:
Agent Ref:

33743-507 CIP/
United States of America

CIP
11/827892
13-Jul-2007

2008-0183395
31-Jul-2008

Published

IRE CAK LLM
JRC IF

Owner Name:
Client Name: Source MDX

Attorney(s): IRE CAK LLM
JRC IF
KAH

Agent Name:

Title: Gene Expression Profiling For Identification, Monitoring
And Treatment Of Multiple Sclerosis

Client Ref:
Agent Ref:

Docket Number/Subcase
Country Name

Case
Type

Serial Number
Filing Date

Publication
Number/Date

Patent
Number/Date

Status
Expiration Date

Report Selection

38

Thursday, May 05, 2011 RecordCount:

by Docket Number
by Country
by Client
by Owner
by Inventor

Report Format
Concise
Comprehensiv

Inventors
Print
Do Not Print

Remarks
Print
Do Not Print

Include Design. Countries

Preview before printing

Yes No

Date Range Filing Issue
From: To:

Expiration
To:

Last Update

Country:
Area:
Owner:
Inventor:
Docket 33743-501
Number(s): 33743-501 CIP2
33743-501 PRO
33743-503
33743-503 CIP
33743-503 CIP 2
33743-503 CIP DIV
33743-503 CIP DIV 2
33743-503 CIP DIV 3
33743-503 CIP DIV 4
33743-503 CIP DIV 5
33743-503 CIP DIV 6
33743-503 CIP DIV 7
33743-503 DIV
33743-503 PRO A
33743-503 PRO B
33743-504
33743-504 CIP
33743-504 CON
33743-504 CON 2
33743-504 PRO A
33743-504 PRO B
33743-504 PRO C

Case Type:
Attorney:
Agent:
Client(s):

Status Codes:
Active
Inactive
All
Status(es):

33743-504 PRO D
33743-507
33743-507 CIP
33743-507 PRO
33743-507 PRO C